Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44850 | 1.00 | MALT1 (0.35) | MALT1TRPA1AVPR1ALMNASMN1; SMN2 | |
| SCHEMBL951154 | 0.86 | MALT1 (0.34) | MALT1TRPA1RARGRORC | |
| SCHEMBL340411 | 0.86 | ALOX15 (0.45) | MALT1TRPA1AVPR1AALOX15KDM4E | |
| SCHEMBL340412 | 0.86 | ALOX15 (0.45) | MALT1TRPA1AVPR1AALOX15KDM4E | |
| SCHEMBL951152 | 0.86 | MALT1 (0.34) | MALT1TRPA1RARGRORC | |
| SCHEMBL17135611 | 0.86 | LMNA (0.39) | MALT1TRPA1LMNASMN1; SMN2MEN1 | |
| SCHEMBL12528590 | 0.85 | MALT1 (0.36) | MALT1TRPA1LMNASMN1; SMN2MEN1 | |
| SCHEMBL384656 | 0.80 | KMT2A (0.43) | MALT1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL958268 | 0.80 | MALT1 (0.40) | MALT1TRPA1LMNASMN1; SMN2RARG | |
| SCHEMBL29558300 | 0.80 | MALT1 (0.40) | MALT1TRPA1LMNASMN1; SMN2RARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582688-B1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | BAYER IP GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8791139-B2 | Anthranilic diamide derivatives | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| EP-2582688-A1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | Bayer Intellectual Property GmbH (DE) | 2013-04-24 | — | — | EP | disclosed |
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2012-01-19 | — | — | US | disclosed |
| WO-2011157654-A1 | ANTHRANILIC ACID DIAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015980-A1 | ANTHRANILIC DIAMIDE DERIVATIVES | DDT, QDPR, ANTXR2 | MALT1 4605/4885TRPA1 1434/4885AVPR1A 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.